Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call
Neuronetics (NASDAQ: STIM), a medical technology company specializing in neurohealth disorders treatment solutions, has announced it will release its fourth quarter 2024 financial and operating results before the market opens on Tuesday, March 4, 2025.
The company will host a conference call to discuss the results at 8:30 a.m. Eastern Time on the same day. Investors can access the live webcast in listen-only mode, and telephone participants are encouraged to register and join 10 minutes before the event start.
Neuronetics (NASDAQ: STIM), una società di tecnologia medica specializzata in soluzioni per il trattamento dei disturbi neuro-salutari, ha annunciato che pubblicherà i suoi risultati finanziari e operativi del quarto trimestre 2024 prima dell'apertura del mercato martedì 4 marzo 2025.
La società ospiterà una conferenza telefonica per discutere i risultati alle 8:30 del mattino, ora orientale dello stesso giorno. Gli investitori possono accedere alla diretta web in modalità ascolto e i partecipanti telefonici sono incoraggiati a registrarsi e unirsi 10 minuti prima dell'inizio dell'evento.
Neuronetics (NASDAQ: STIM), una empresa de tecnología médica especializada en soluciones para el tratamiento de trastornos neuro-saludables, ha anunciado que publicará sus resultados financieros y operativos del cuarto trimestre de 2024 antes de la apertura del mercado el martes 4 de marzo de 2025.
La empresa llevará a cabo una conferencia telefónica para discutir los resultados a las 8:30 a.m. hora del Este el mismo día. Los inversores pueden acceder a la transmisión web en modo solo escucha, y se anima a los participantes telefónicos a registrarse y unirse 10 minutos antes del inicio del evento.
Neuronetics (NASDAQ: STIM)은 의료 기술 회사로서 신경 건강 장애 치료 솔루션을 전문으로 하며, 2025년 3월 4일 화요일 시장 개장 전에 2024년 4분기 재무 및 운영 결과를 발표할 것이라고 발표했습니다.
회사는 같은 날 동부 표준시 기준 오전 8시 30분에 결과를 논의하기 위한 전화 회의를 개최할 예정입니다. 투자자들은 청취 전용 모드로 생중계에 접근할 수 있으며, 전화 참가자들은 이벤트 시작 10분 전에 등록하고 참여할 것을 권장합니다.
Neuronetics (NASDAQ: STIM), une entreprise de technologie médicale spécialisée dans les solutions de traitement des troubles neuro-santé, a annoncé qu'elle publiera ses résultats financiers et opérationnels du quatrième trimestre 2024 avant l'ouverture du marché le mardi 4 mars 2025.
L'entreprise organisera une conférence téléphonique pour discuter des résultats à 8h30, heure de l'Est le même jour. Les investisseurs peuvent accéder à la diffusion en direct en mode écoute seule, et les participants par téléphone sont encouragés à s'inscrire et à rejoindre 10 minutes avant le début de l'événement.
Neuronetics (NASDAQ: STIM), ein Medizintechnikunternehmen, das sich auf Lösungen zur Behandlung von neurogesundheitlichen Störungen spezialisiert hat, hat angekündigt, dass es seine finanziellen und operativen Ergebnisse für das vierte Quartal 2024 vor der Markteröffnung am Dienstag, den 4. März 2025, veröffentlichen wird.
Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können auf das Live-Webcast im Nur-Zuhören-Modus zugreifen, und telefonische Teilnehmer werden ermutigt, sich 10 Minuten vor Beginn der Veranstaltung zu registrieren und beizutreten.
- None.
- None.
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.9 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
When will Neuronetics (STIM) release Q4 2024 earnings?
What time is Neuronetics (STIM) Q4 2024 earnings call?
How can investors access Neuronetics (STIM) Q4 2024 earnings call?
What is the recommended join time for STIM's Q4 2024 earnings call?
